Clinical Trial Search

Primary: Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h)) — 0.234; 0.122; 0.155; -0.028 Liters

Primary: Trough FEV1 Response — 0.071; 0.125; 0.136; 0.155 Litres

Primary: Cmax,ss (Olodaterol) — 4.33; 2.82 picogram/milliliter (pg/mL)

Primary: Maximum Severity of Post-operative Pain — 37; 26; 13; 21 participants — p=0.033

Primary: Overall Survival (OS) — 13.3; 11.7 months — p=0.0219

Primary: Number (%) of Patients With Drug-related AEs — 4.9; 5.0; 7.3 percentage of participants

Primary: Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) — -1.51; -2.40 percentage change — p=<0.001

Primary: Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse…

Primary: PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA — 232; 27; 10; 24 participants

Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6 — 24.66; 24.59; -7.61; -7.35 mmHg

Primary: Estimate the Effect Size Associated With Objective Measures and Patient Self-reports of Clinical Outcomes Including Seizure Frequency, Seizure Severity, Seizure…

Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels

Primary: Mean HAM-D17 Total Score Change (Intent to Treat - All) — -7.49; -6.97 units on a scale

Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants

Primary: Primary Effectiveness Endpoint — 54.0 percentage of stent patency